Efficient transformation of mammalian cells with constructs containing a puromycin-resistance marker.
Recombinant plasmids have been obtained that lead to the accumulation of five- to ten-fold more puromycin-N-acetyl-transferase (PAC) mRNA and two- to three-fold more PAC activity than the already described plasmid pSV2pac [Vara et al., Nucl. Acids Res. 14 (1986) 4117-4124]. When these optimized recombinants were used for stable transformation to puromycin resistance, efficiencies up to 1 x 10(-2) were obtained, indicating that these pac-containing recombinants may be very useful dominant selectable markers for gene transfer in mammalian cells.
de la Luna
S
S
Centro de Biología Molecular (CSIC-UAM), Universidad Autónoma, Madrid, Spain.
Soria
I
I
Pulido
D
D
Ortín
J
J
Jiménez
A
A
D000123:Acetyltransferases / Q000096:biosynthesis / Q000235:genetics*; D000818:Animals; D002460:Cell Line; D006224:Cricetinae; D004351:Drug Resistance; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D005822:Genetic Vectors; D007668:Kidney; D007739:L Cells / Q000187:drug effects / Q000378:metabolism; D008647:Mesocricetus; D051379:Mice; D010957:Plasmids; D011691:Puromycin / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics; D014170:Transformation, Genetic; D014709:Vero Cells / Q000187:drug effects / Q000378:metabolism
D011993:Recombinant Fusion Proteins; D011691:Puromycin; D000123:Acetyltransferases; C045336:puromycin N-acetyltransferase